uniQure to Present at the BioEquity Europe and Jefferies Global Healthcare Conferences

        Print
| Source: uniQure

AMSTERDAM, The Netherlands, May 15, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present a corporate overview at the 15th BioEquity Europe Conference, May 21-22, 2014, to be held at the Hilton Amsterdam Hotel, Amsterdam, the Netherlands, as well as at Jefferies 2014 Global Healthcare Conference, June 2-5, 2014, to be held at the Grand Hyatt New York, New York City, NY, USA.

BioEquity Europe 2014

Date:                                              May 21, 2014
Time:                                             2:00 p.m. (CEST)
Location:                                      Hilton Amsterdam Hotel, Amsterdam, the Netherlands, Ballroom A
Speaking for uniQure:                 Joern Aldag, Chief Executive Officer

Jefferies 2014 Global Healthcare Conference

Date:                                              June 2, 2014
Time:                                              9:30 a.m. (EDT)
Location:                                      Grand Hyatt New York, New York City, New York, USA, Ballroom 5
Speaking for uniQure:                 Joern Aldag, Chief Executive Officer

To access a simultaneous webcast of Mr. Aldag's presentation via the internet, log on to the "Events" section on the Media page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/.

A replay of the webcast will be available from uniQure's website for 30 days following the respective conference. Mr. Aldag's presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of uniQure's website at http://www.uniqure.com/news/calendar-of-events/.

About uniQure

uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com

uniQure:
Aicha Diba                                                  
Investor Relations                                        
Direct : +31 20 566 8014                               
Main: +31 20 566 7394                                 
IR@uniQure.com     
                                    
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +1 781 235 3060
gschweitzer@macbiocom.com

HUG#1785856